MDWD (MediWound) 5-Day RSI: 66.51 (As of Jul. 06, 2026)


MDWD MediWound Ltd MDWD
56 GF Score
Price $15.16
GF Value $12.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound 5-Day RSI?

MediWound MDWD +2.19% 56 5-Day RSI is 66.51 as of Jul. 06, 2026. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,419 Biotechnology companies, MediWound ranks worse than 65.4% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-06), MediWound's 5-Day RSI is 66.51.

The industry rank for MediWound's 5-Day RSI or its related term are showing as below:

MDWD's 5-Day RSI is ranked worse than
65.4% of 1419 companies
in the Biotechnology industry
Industry Median: 58.13 vs MDWD: 66.51

MediWound  (NAS:MDWD) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


MediWound 5-Day RSI Related Terms


MDWD vs UNCY, ARCT, NGEN: 5-Day RSI Comparison

For the Biotechnology subindustry, MediWound's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediWound 5-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediWound's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where MediWound's 5-Day RSI falls into.


MDWD
56GF Score
MediWound Ltd MDWD
5-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediWound  (NAS:MDWD) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 5-Day RSI →
What does a 5-Day RSI of 66.51 mean?
MediWound (MDWD) has a 5-Day RSI of 66.51 as of Jul. 06, 2026. According to the industry distribution chart, MediWound ranks #928 out of 1419 companies in the Biotechnology industry, placing it in the top 65.4%.
Is MediWound's 5-Day RSI too high?
MediWound's current 5-Day RSI is 66.51. The Biotechnology industry median 5-Day RSI is 58.13. MediWound's value of 66.51 is 14.4% above this industry median. Based on the distribution chart, MediWound ranks #928 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's 5-Day RSI compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #928 out of 1419 companies for 5-Day RSI. This places MediWound in the lower half of its industry. The industry median 5-Day RSI is 58.13. MediWound's value of 66.51 is 14.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 58.13, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediWound's current 5-Day RSI of 66.51 is 14.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 58.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current 5-Day RSI is 66.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current 5-Day RSI is 66.51 and 14.4% above the Biotechnology industry median of 58.13. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For MediWound (MDWD), the current 5-Day RSI is 66.51 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

  • 5-Day RSI: 66.51
  • GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
  • GF Score™: 56/100 with 7 warning signs
  • Industry Position: 14.4% above the Biotechnology median (#928 of 1419)

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MediWound Business Description

Other Exchanges M8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score

Get the complete analysis for MDWD

5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.16
Price
$12.44
GF Value